143 related articles for article (PubMed ID: 38010978)
1. Impact of socio-economic environment on incidence of primary liver cancer in France between 2006 and 2016.
Comoz B; Ollivier-Hourmand I; Bouvier AM; Nousbaum JB; Nguyen TTN; Launoy G; Bouvier V; Bryere J
Liver Int; 2024 Feb; 44(2):446-453. PubMed ID: 38010978
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
3. Time and deprivation trends in incidence of primary liver cancer subtypes in England.
Konfortion J; Coupland VH; Kocher HM; Allum W; Grocock MJ; Jack RH
J Eval Clin Pract; 2014 Aug; 20(4):498-504. PubMed ID: 24902884
[TBL] [Abstract][Full Text] [Related]
4. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
5. Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Pomyen Y; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Sripan D; Chornkrathok C; Budhu A; Budhisawasdi V; Lertprasertsuke N; Chotirosniramit A; Pairojkul C; Auewarakul CU; Ungtrakul T; Sricharunrat T; Phornphutkul K; Sangrajang S; Loffredo CA; Harris CC; Mahidol C; Wang XW; Ruchirawat M;
Sci Rep; 2023 Jul; 13(1):11406. PubMed ID: 37452065
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
[TBL] [Abstract][Full Text] [Related]
7. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
8. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Mahmoudi S; Bernatz S; Althoff FC; Koch V; Grünewald LD; Scholtz JE; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Eur J Radiol; 2022 Nov; 156():110556. PubMed ID: 36270195
[TBL] [Abstract][Full Text] [Related]
9. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
[TBL] [Abstract][Full Text] [Related]
10. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
11. Treating Hepatobiliary Cancers: The Oncology Way.
Galle PR
Dig Dis; 2017; 35(4):384-386. PubMed ID: 28468016
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.
Jarnagin WR; Weber S; Tickoo SK; Koea JB; Obiekwe S; Fong Y; DeMatteo RP; Blumgart LH; Klimstra D
Cancer; 2002 Apr; 94(7):2040-6. PubMed ID: 11932907
[TBL] [Abstract][Full Text] [Related]
13. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
14. Rising incidence of primary liver cancer in Brunei Darussalam.
Chong RJ; Abdullah MS; Hossain MM; Telisinghe PU; Chong VH
Asian Pac J Cancer Prev; 2013; 14(6):3473-7. PubMed ID: 23886131
[TBL] [Abstract][Full Text] [Related]
15. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
16. Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Mahmoudi S; Bernatz S; Ackermann J; Koch V; Dos Santos DP; Grünewald LD; Yel I; Martin SS; Scholtz JE; Stehle A; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Clin Oncol (R Coll Radiol); 2023 May; 35(5):e312-e318. PubMed ID: 36804153
[TBL] [Abstract][Full Text] [Related]
17. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
18. Have incidence rates of liver cancer peaked in the United States?
Petrick JL; Florio AA; Loomba R; McGlynn KA
Cancer; 2020 Jul; 126(13):3151-3155. PubMed ID: 32294255
[TBL] [Abstract][Full Text] [Related]
19. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
Tischoff I; Tannapfel A
Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
[TBL] [Abstract][Full Text] [Related]
20. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
